Speedy EU Assessment On Cards For AZ’s Durvalumab

 
• By Maureen Kenny
  
Business Accelerator Program
Durvalumab could benefit from accelerated assessment in the EU • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer